Urge the FDA to Say YES to Accelerated Approval of RE-024 for treatment of PKAN.

We urge the Food and Drug Administration (FDA) to use the Accelerated Approval pathway for approval and access to the drug RE-024 for treatment of Pantothenate kinase-associated neurodegeneration (PKAN). RE-024 gives PKAN patients a chance to survive; a chance they do not have without the drug. Furthermore, we ask for approval of the Physician’s IND submitted by Dr. Michael Kruer for the Kulsrud Brothers of Grace City, ND. RE-024 has now been administered to two patients in Europe who are both showing signs of improvement. It’s time for the FDA to say YES to PKAN patients in the United States and make this the first generation of PKAN survivors!